Profile data is unavailable for this security.
About the company
Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.
- Revenue in HKD (TTM)10.84m
- Net income in HKD-277.69m
- Incorporated2014
- Employees219.00
- LocationAscletis Pharma Inc12F, Building D198 Qidi Road, HIPARKHANGZHOU ChinaCHN
- Websitehttps://www.ascletis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hbm Holdings Ltd | 562.07m | 165.79m | 918.02m | 158.00 | 5.33 | 0.9218 | 4.68 | 1.63 | 0.2254 | 0.2254 | 0.7624 | 1.30 | 0.3258 | 3.96 | 16.67 | 3,175,517.00 | 9.59 | -54.61 | 13.25 | -66.04 | 95.57 | 97.81 | 29.42 | -400.28 | 3.44 | 8.14 | 0.3502 | -- | 120.13 | 127.06 | 116.61 | -- | -12.62 | -- |
| SinoMab Bioscience Ltd | 2.18m | -214.48m | 1.18bn | 214.00 | -- | 3.96 | -- | 541.71 | -0.2059 | -0.2059 | 0.0021 | 0.2725 | 0.0023 | -- | -- | 10,123.74 | -22.83 | -24.62 | -29.11 | -27.72 | 26.80 | -- | -9,853.75 | -4,451.74 | -- | -81.79 | 0.6339 | -- | -- | -- | 14.45 | -- | 106.81 | -- |
| Jbm (Healthcare) Ltd | 720.54m | 163.88m | 1.38bn | 279.00 | 8.59 | 1.38 | 6.32 | 1.92 | 0.1955 | 0.1955 | 0.8564 | 1.22 | 0.5069 | 4.64 | 4.38 | 2,582,581.00 | 12.10 | 4.38 | 15.12 | 5.52 | 51.75 | 46.47 | 23.86 | 12.69 | 1.27 | 54.59 | 0.0768 | 32.98 | 24.62 | 16.09 | 128.51 | 19.99 | 2.26 | -- |
| Essex Bio-Technology Ltd | 1.62bn | 262.89m | 1.59bn | 1.46k | 6.22 | 0.7885 | 5.00 | 0.9813 | 0.4499 | 0.4499 | 2.73 | 3.55 | 0.5587 | 2.62 | 2.73 | 1,093,064.00 | 9.07 | 11.20 | 12.10 | 14.73 | 89.78 | 86.01 | 16.24 | 19.77 | 1.61 | -- | 0.1397 | 16.16 | 29.51 | 7.72 | 22.11 | 3.56 | 7.29 | 7.39 |
| Ascletis Pharma Inc | 10.84m | -277.69m | 1.65bn | 219.00 | -- | 0.7307 | -- | 152.06 | -0.2675 | -0.2675 | 0.0104 | 2.31 | 0.0041 | 1.34 | 3.58 | 49,497.94 | -10.47 | -6.43 | -10.85 | -6.64 | -125.17 | 35.67 | -2,561.69 | -243.38 | 24.31 | -- | 0.004 | -- | 4.63 | -19.39 | 54.04 | -- | -20.44 | -- |
| Jacobson Pharma Corporation Ltd | 1.56bn | 253.22m | 1.66bn | 1.72k | 6.42 | 0.6778 | 4.20 | 1.06 | 0.1292 | 0.1292 | 0.7988 | 1.22 | 0.4116 | 2.84 | 7.32 | 907,070.30 | 6.67 | 4.30 | 8.55 | 5.57 | 42.92 | 41.25 | 16.20 | 13.73 | 1.46 | 9.53 | 0.2218 | 40.62 | 15.79 | -0.1401 | 1.31 | -3.05 | 24.06 | 4.10 |
| Cryofocus Medtech Shanghai Co Ltd | 44.60m | -114.15m | 1.67bn | 370.00 | -- | 13.20 | -- | 37.48 | -0.4774 | -0.4774 | 0.1865 | 0.5294 | 0.1881 | 0.418 | 4,369.58 | 113,767.20 | -51.79 | -- | -66.30 | -- | 76.35 | -- | -275.28 | -- | 2.06 | -80.68 | 0.2303 | -- | 50.83 | -- | 13.13 | -- | -- | -- |
| VIVA Biotech Holdings | 2.14bn | -341.64k | 1.75bn | 2.04k | -- | 0.4315 | 7.00 | 0.8173 | -0.0054 | -0.0054 | 1.04 | 1.90 | 0.2603 | 5.26 | 5.18 | 1,032,034.00 | 0.4017 | -1.39 | 0.5601 | -1.68 | 33.66 | 34.81 | 1.54 | -5.44 | 1.46 | 3.19 | 0.2884 | -- | -9.42 | 59.31 | 78.03 | -- | 31.98 | -- |
| Dawnrays Pharmaceutical (Holdings) Ltd | 1.16bn | 604.96m | 1.82bn | 1.18k | 3.00 | 0.5171 | 2.66 | 1.57 | 0.4027 | 0.4027 | 0.7715 | 2.34 | 0.2838 | 2.05 | 6.17 | 1,013,872.00 | 14.74 | 9.89 | 17.79 | 12.49 | 56.58 | 56.69 | 51.92 | 27.89 | 3.04 | -- | 0.0544 | 35.33 | -9.90 | 3.94 | -8.95 | 1.41 | 63.92 | 2.00 |
| Golden Throat Holdings Group Co Ltd | 1.08bn | 281.71m | 2.31bn | 860.00 | 8.19 | 1.67 | 7.13 | 2.13 | 0.381 | 0.381 | 1.46 | 1.86 | 0.4994 | 3.23 | 4.07 | 1,244,013.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
Data as of Nov 26 2024. Currency figures normalised to Ascletis Pharma Inc's reporting currency: Hong Kong Dollar HKD
1.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 3.29m | 0.33% |
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 2.99m | 0.30% |
| JPMorgan Asset Management (China) Co Ltd.as of 30 Jun 2024 | 2.27m | 0.23% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 1.82m | 0.19% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 252.65k | 0.03% |
| American Century Investment Management, Inc.as of 07 Nov 2024 | 186.00k | 0.02% |
| DFA Australia Ltd.as of 30 Sep 2024 | 15.96k | 0.00% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
